Abg Management Ltd Who Is Sorrento Therapeutics, Inc. (SRNE) Insider, Unloaded 662,912 Shares of the Company; Last Week GEODRILL Limited (TSE:GEO) Coverage

662,912 shares of Sorrento Therapeutics Inc were sold by Abg Management Ltd, a corporation’s insider. The mentioned shares are valued at approximately $4,542,234 which has been calculated based on the average transactions’ share price of $6.9. At present, Abg Management Ltd owns 7.09 million shares which are around 10%+ of Sorrento Therapeutics Inc’s total market capitalization. A document available for free here shows this insider activity, that took place on February 8, 2018 and was filed with the DC-based SEC.

Among 2 analysts covering Geodrill (TSE:GEO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Geodrill had 5 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 22 by Paradigm Research. TD Securities upgraded GEODRILL Limited (TSE:GEO) on Thursday, May 12 to “Speculative Buy” rating. See GEODRILL Limited (TSE:GEO) latest ratings:

Since January 23, 2018, it had 0 insider purchases, and 3 selling transactions for $8.11 million activity. 310,000 shares were sold by ABG Management Ltd, worth $2.37M. Asia Pacific MedTech (BVI) Ltd also sold $5.18 million worth of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) shares.

The stock increased 2.84% or $0.2 during the last trading session, reaching $7.25. About 1.78 million shares traded. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has declined 73.31% since February 8, 2017 and is downtrending. It has underperformed by 90.01% the S&P500.

Investors sentiment decreased to 0.67 in 2017 Q3. Its down 0.11, from 0.78 in 2017Q2. It turned negative, as 9 investors sold Sorrento Therapeutics, Inc. shares while 12 reduced holdings. 3 funds opened positions while 11 raised stakes. 8.31 million shares or 22.78% less from 10.76 million shares in 2017Q2 were reported. Vanguard Gp invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Matrix Asset Inc Ny invested in 72,000 shares. Moreover, Wells Fargo & Mn has 0% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Art Advsrs Ltd Liability Com owns 0.01% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 123,455 shares. Jpmorgan Chase & Co owns 76,169 shares or 0% of their US portfolio. Renaissance Techs Ltd Liability reported 0% stake. Glenmede Tru Na holds 0% or 29,135 shares in its portfolio. Citadel Advsr Lc has 32,723 shares for 0% of their portfolio. Deutsche Bancorporation Ag reported 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Tower Rech Cap Limited Company (Trc) reported 0% stake. 43,348 were accumulated by Virtu Limited Com. Millennium Mngmt Limited Company accumulated 0% or 552,649 shares. California Employees Retirement Systems invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Geode Capital Management Limited Liability Co reported 460,620 shares. Crow Point Prtnrs Ltd Liability stated it has 0.01% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE).

Among 9 analysts covering Sorrento Therapeutics (NASDAQ:SRNE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sorrento Therapeutics has $45.0 highest and $6.0 lowest target. $20.25’s average target is 179.31% above currents $7.25 stock price. Sorrento Therapeutics had 24 analyst reports since July 29, 2015 according to SRatingsIntel. Rodman & Renshaw reinitiated it with “Buy” rating and $45.0 target in Monday, December 7 report. The stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) earned “Buy” rating by H.C. Wainwright on Thursday, June 15. Roth Capital initiated Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Thursday, August 3. Roth Capital has “Buy” rating and $700 target. Rodman & Renshaw maintained the shares of SRNE in report on Tuesday, April 5 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 30. H.C. Wainwright maintained the stock with “Buy” rating in Monday, September 18 report. Oppenheimer maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Tuesday, August 29. Oppenheimer has “Buy” rating and $7.0 target. The rating was maintained by Oppenheimer on Friday, January 19 with “Buy”. The firm has “Buy” rating given on Tuesday, January 23 by H.C. Wainwright. H.C. Wainwright maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Tuesday, June 27. H.C. Wainwright has “Buy” rating and $2000 target.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $599.52 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It currently has negative earnings. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.